Skip to main content
SpringerLink
Log in

Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole

  • Chapter
Oxidative Stress and Neuroprotection

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURALTRANS,volume 71))

Summary

1202 patients suffering from Parkinson’s disease switched from other dopamine agonists to pramipexole under open conditions either abruptly or in an overlapping, gradual manner. Mostly insufficient effectiveness motivated the switch. The investigators gave equal preference to either an abrupt or an overlapping switch to pramipexole in this observational study. There was a tendency in favour of the overlapping switch procedure in those patients who were on a relatively higher dose of a dopamine agonist before the switch. The switch was performed because the investigators expected the effect of pramipexole on tremor, motor functions and depression/anhedonia to be better compared with previous dopamine agonists. The main reasons for switching to pramipexole (anti-tremor effect, anti-depressive/anti-anhedonic effect) as given by the physicians at baseline came up to expectations.

The switch to pramipexole mostly yielded further improvements irrespective of the mode of switching.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • American Academy of Neurology, Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence based review. Neurology 58: 11–17

    Article  PubMed  CAS  Google Scholar 

  • Agency for Healthcare Research and Quality (2003) Diagnosis and Treatment of Parkinson’s Disease: A Systematic Review of the Literature. Summary, Evidence Report/Technology Assessment: Number 57. AHRQ Publication Number 03-E039. Rockville, MD

    Google Scholar 

  • Bain P (1993) A combined clinical and neurophysiological approach to the study of patients with tremor. J Neurol Neurosurg Psychiatry 56: 839–844

    PubMed  CAS  Google Scholar 

  • Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey Jr RB (2004) Pergolide use in Parkinson’s disease is associated with cardiac valve regurgitation. Neurology 63: 301–304

    PubMed  CAS  Google Scholar 

  • Brecht HM (2001) Dopaminagonisten im Vergleich. In: Riederer P, Laux G, Pöldinger W (eds) Neuro-Psychopharmaka 5: 226–237

    Google Scholar 

  • Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, van Zandijcke M, de Sutter J, Santens P, Decoodt P, Moerman Ch Schoors D (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular disease. The Lancet 363: 1179–1183

    Article  CAS  Google Scholar 

  • Canesi M, Antonini A, Mariani CB, Tesei S, Zecchinelli AL, Barichella M, Pezzoli G (1999) An overnight switch to ropinirole therapy in patients with Parkinson’s disease. Short communication. J Neural Transm 106: 925–929

    Article  PubMed  CAS  Google Scholar 

  • Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans D (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11: 58–65

    Article  CAS  Google Scholar 

  • Etminan M, Sudeep G, Samii A (2003) Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease. A Meta-Analysis. Drug Safety 26: 439–444

    Article  PubMed  CAS  Google Scholar 

  • Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78: 730–731

    Article  PubMed  Google Scholar 

  • German Society of Neurology (2003) Leitlinien für Diagnostik und Therapie in der Neurologie; 2. revised and enlarged edition, Thieme, Stuttgart, New York

    Google Scholar 

  • Gimenez-Roldan S, Esteban EM, Mateo D (2001) Switching from bromocriptine to ropinirole in patients with advanced Parkinson’s disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 24: 346–351

    Article  PubMed  CAS  Google Scholar 

  • Goetz CG, Blasucci L, Stebbins GT (1999) Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow? Neurology 52: 1227–1229

    PubMed  CAS  Google Scholar 

  • Grosset K, Needleman F, Macphee G, Grosset D (2004) Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: A clinical series and five-drug dose conversion table. Mov Disord 19: 1370–1374

    Article  PubMed  Google Scholar 

  • Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson’s disease. J Neural Transm 108: 63–70

    Article  PubMed  CAS  Google Scholar 

  • Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19: 656–662

    Article  PubMed  Google Scholar 

  • Kraus P, Hoffmann A (2006) (in preparation) Spiralometry: A new technique for a computer based evaluation of paper-pencil spirals

    Google Scholar 

  • Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H (2005) Anhedonia, Depression and Motor Functioning in Parkinson’s Disease during treatment with Pramipexole. J Neuropsychiatry Clin Neurosci 17: 214–220

    PubMed  CAS  Google Scholar 

  • Linazasoro G (2004) Spanish Dopamine Agonists Study Group: conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson’s disease. J Neurol 251: 335–339

    Article  PubMed  CAS  Google Scholar 

  • Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martínez-Martín P, Bonuccelli U, Kraus PH, van Hilten JJ (2004) A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 75: 388–395

    Article  PubMed  CAS  Google Scholar 

  • Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajines ME, Huff RM (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290: 29–36

    Article  PubMed  CAS  Google Scholar 

  • Müller Th, Fritze J (2003) Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clinical Neuropharmacol 26: 109–111

    Article  Google Scholar 

  • Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 56[Suppl 5]: S1–S88

    PubMed  CAS  Google Scholar 

  • Pogarell O, Gasser T, Van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH (2002) Pramipexole in patientswith Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72: 713–720

    Article  PubMed  CAS  Google Scholar 

  • Rabey JM, Bass H, Bonucelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, van Sauten W, van Hilten B (1997) Evaluation of the short Parkinson’s Evaluation Scale: a new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials. Clin Neuropharmacol 20: 322–337

    Article  PubMed  CAS  Google Scholar 

  • Rascol O, Pathak A, Bagheri H, Montastruc JL (2004) New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 19: 611–613

    Article  PubMed  Google Scholar 

  • Reichmann H, Brecht HM, Köster J, Kraus PH (2003) Pramipexole in routine clinical practice. CNS Drugs 17: 965–973

    Article  PubMed  CAS  Google Scholar 

  • Reichmann H, Herting B, Miller A, Sommer U (2003) Switching and combining dopamine agonists. J Neural Transm 110: 1393–1400

    Article  PubMed  CAS  Google Scholar 

  • Reichmann H, Sommer U, Fuchs G, Hefter H, Mark G, Muller T, Thumler R, Ulm G, Vieregge P (2000) Workshop IV: drug treatment guidelines for the long-term management of parkinson’s disease. J Neurol 247[Suppl 4]: 40–41

    Google Scholar 

  • Rektorova I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdiovà Z, Fiedler J, Klaiblova H, Kulisták P, Ressner P, Svátová J, Urbánek K, Velísková J (2003) Depression in Parkinson’s disease: an eight-month, randomised, open-label, national multi-centre comparative study of pramipexole and pergolide. Eur J Neurol 10: 399–406

    Article  PubMed  CAS  Google Scholar 

  • Stewart D, Morgan E, Burn D, Grosset D, Chaudhuri KR, MacMahon D, Needleman F, Macphee G, Heywood P (2004) Dopamine agonist switching in Parkinson’s disease. Hosp Med 65: 215–219

    PubMed  Google Scholar 

  • Tan EK, Ratnagopal P, Han SY, Wong MC (2003) Piribedil and bromocriptine in Parkinson’s disease: a single-blind crossover study. Acta Neurol Scand 107: 202–206

    Article  PubMed  CAS  Google Scholar 

  • Tetrud JW, Zhang J, Gomez-Mancilla B, Greenfield JC (2000) Abrupt conversion of Parkinson’s disease patients to pramipexole from bromocriptine or pergolide: Safety, tolerance, and optimal conversion ratio. Neurology 54[Suppl 3]: 279–280

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany

    H. Reichmann

  2. Department of Neurology, Central Hospital Bremerhaven, Germany

    P. Odin

  3. Division Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

    H. M. Brecht & J. Köster

  4. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany

    P. H. Kraus

Authors
  1. H. Reichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Odin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. M. Brecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Köster
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. H. Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute Alfred Fessard de Neurosciences, CNRS, Gif Yvette, France

    H. Parvez

  2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Germany

    P. Riederer

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag

About this chapter

Cite this chapter

Reichmann, H., Odin, P., Brecht, H.M., Köster, J., Kraus, P.H. (2006). Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. In: Parvez, H., Riederer, P. (eds) Oxidative Stress and Neuroprotection. Journal of Neural Transmission. Supplementa, vol 71. Springer, Vienna. https://doi.org/10.1007/978-3-211-33328-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-33328-0_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-33327-3

  • Online ISBN: 978-3-211-33328-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation